Travere Therapeutics Q3 2024 GAAP EPS $(0.70), Inline, Sales $62.90M Beat $59.70M Estimate
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics reported Q3 2024 earnings with a GAAP EPS of $(0.70), meeting analyst expectations. The company achieved sales of $62.90 million, surpassing the $59.70 million estimate and marking a 69.56% increase from the previous year.
October 31, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics reported Q3 2024 earnings with a GAAP EPS of $(0.70), meeting analyst expectations. The company achieved sales of $62.90 million, surpassing the $59.70 million estimate and marking a 69.56% increase from the previous year.
The earnings per share met expectations, which is neutral, but the significant sales beat and year-over-year growth are positive indicators for the stock. This suggests a likely positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100